

Supplementary Table 3. Baseline characteristics of patients with NVAf newly prescribed a NOAC according to whether they were appropriately dosed or inappropriately underdosed or overdosed.

	Appropriately dosed N=24,217		Inappropriately underdosed N=4114		Overdosed N=2136		Total N=30,467	
	n	%	n	%	n	%	n	%
Sex								
Male	13,687	56.5	1917	46.6	1052	49.3	16,656	54.7
Female	10,530	43.5	2197	53.4	1084	50.7	13,811	45.3
Age (years)								
<60	2411	10.0	175	4.3	68	3.2	2654	8.7
60–69	5244	21.7	455	11.1	218	10.2	5917	19.4
70–79	8273	34.2	1097	26.7	847	39.7	10,217	33.5
≥80	8289	34.2	2387	58.0	1003	47.0	11,679	38.3
OAC naïve status								
Naïve	11,924	49.2	2038	49.5	845	39.6	14,807	48.6
Non-naïve	12,293	50.8	2076	50.5	1291	60.4	15,660	51.4
Year of first NOAC prescription								
2011–2013	3413	14.1	513	12.5	527	24.7	4453	14.6
2014–2016	20,804	85.9	3601	87.5	1609	75.3	26,014	85.4
BMI, kg/m²								
<20 (underweight)	5553	22.9	1047	25.4	502	23.5	7102	23.3
20–24 (healthy weight)	989	4.1	201	4.9	79	3.7	1269	4.2
25–29 (overweight)	8456	34.9	1530	37.2	739	34.6	10,725	35.2
≥30 (obese)	8296	34.3	1134	27.6	739	34.6	10,169	33.4
Missing	923	3.8	202	4.9	77	3.6	1202	3.9
Smoking								
Non-smoker	9904	40.9	1770	43.0	852	39.9	12,526	41.1
Smoker	1933	8.0	273	6.6	131	6.1	2337	7.7
Ex-smoker	12,359	51.0	2068	50.3	1151	53.9	15,578	51.1
Unknown	21	0.1	3	0.1	2	0.1	26	0.1
Alcohol (units/week)								
None	4780	19.7	1042	25.3	526	24.6	6348	20.8
1–9	10,870	44.9	1827	44.4	978	45.8	13,675	44.9
10–20	3968	16.4	517	12.6	260	12.2	4745	15.6
21–41	1541	6.4	180	4.4	115	5.4	1836	6.0
≥42	674	2.8	88	2.1	55	2.6	817	2.7
Unknown	2384	9.8	460	11.2	202	9.5	3046	10.0
CVD								
IHD								
Heart failure	3853	15.9	780	19.0	549	25.7	5182	17.0
Hypertension	15,920	65.7	2857	69.4	1617	75.7	20,394	66.9
Ischaemic stroke	3445	14.2	754	18.3	388	18.2	4587	15.1

	Appropriately dosed N=24,217		Inappropriately underdosed N=4114		Overdosed N=2136		Total N=30,467	
History of bleeding (GI, intracranial or urogenital)	6037	24.9	1135	27.6	609	28.5	7781	25.5
eGFR, ml/min/1.73m²								
>50	17,707	73.1	2863	69.6	679	31.8	21,249	69.7
30–50	3017	12.5	590	14.3	1175	55.0	4782	15.7
<30	385	1.6	0	0.0	186	8.7	571	1.9
Missing	3108	12.8	661	16.1	96	4.5	3865	12.7
Frailty index								
Fit	4005	16.5	372	9.0	103	4.8	4480	14.7
Mild frailty	8912	36.8	1218	29.6	579	27.1	10,709	35.1
Moderate frailty	7140	29.5	1478	35.9	754	35.3	9372	30.8
Severe frailty	4160	17.2	1046	25.4	700	32.8	5906	19.4
CHA₂DS₂VASc score								
≤2	7436	30.7	703	17.1	246	11.5	8385	27.5
3	5095	21.0	803	19.5	384	18.0	6282	20.6
≥4	11,686	48.3	2608	63.4	1506	70.5	15,800	51.9
HAS-BLED score								
0	10,841	44.8	1529	37.2	588	27.5	12,958	42.5
1–2	8962	37.0	1676	40.7	885	41.4	11,523	37.8
≥3	4414	18.2	909	22.1	663	31.0	5986	19.6

BMI, body mass index; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; GI, gastrointestinal; OAC, oral anticoagulant; NOAC, non-vitamin K oral anticoagulant; NVAf, non-valvular atrial fibrillation; SD, standard deviation